Anti-IL-5 and hypereosinophilic syndromes
Hypereosinophilic syndromes represent a heterogeneous group of disorders characterized by peripheral eosinophilia and end-organ damage associated with eosinophil infiltrations. In many instances, the eosinophilia is refractory to standard therapies and clinicians rely on potentially toxic alternativ...
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 115(2005), 1 vom: 01. Apr., Seite 51-60 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2005
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Review Antibodies, Monoclonal Benzamides Interleukin-5 Piperazines Protein Kinase Inhibitors Pyrimidines Imatinib Mesylate 8A1O1M485B |
| Zusammenfassung: | Hypereosinophilic syndromes represent a heterogeneous group of disorders characterized by peripheral eosinophilia and end-organ damage associated with eosinophil infiltrations. In many instances, the eosinophilia is refractory to standard therapies and clinicians rely on potentially toxic alternatives. This group of disorders has recently gained attention with the description of patients that harbor a genetic rearrangement that produces a constitutively active tyrosine kinase, often responsive to anti-tyrosine kinase therapy. In addition, the recent expansion in our understanding of the mechanisms by which eosinophils develop and become activated, involving the cytokine interleukin-5 (IL-5), has led to advances in therapeutic options. A new therapy currently in clinical trials is the humanized monoclonal antibody against IL-5. This review will discuss the etiology, classification, and treatment options for the hypereosinophilic syndromes, with particular emphasis on anti-interleukin-5 therapy |
|---|---|
| Beschreibung: | Date Completed 30.06.2005 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
| ISSN: | 1521-6616 |